Metastatic Castration-resistant Prostate Cancer — Expanded Access Programs
Overview
Right2Hope maintains a directory of 53 expanded access programs, clinical trials, and compassionate use pathways listed for Metastatic Castration-resistant Prostate Cancer. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with metastatic castration-resistant prostate cancer programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 21 programs are currently active or recruiting, with the remaining 32 in other lifecycle stages. Sponsors actively running programs in this area include University of Utah, AstraZeneca, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Amgen, Astellas Pharma Global Development, Inc., and others.
By recruiting status
Snapshot of where every Metastatic Castration-resistant Prostate Cancer program currently sits in its lifecycle.
- Active / Recruiting21
- Inactive32
Top sponsors
Organisations running the most Metastatic Castration-resistant Prostate Cancer programs in the directory.
- University of Utah4 programs
- AstraZeneca3 programs
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins3 programs
- Amgen2 programs
- Astellas Pharma Global Development, Inc.2 programs
- Fusion Pharmaceuticals Inc.2 programs
- Pfizer2 programs
- Rahul Aggarwal2 programs
- BioNTech SE1 program
- Blue Earth Therapeutics Ltd1 program
Metastatic Castration-resistant Prostate Cancer programs (53)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Phase 2 Study on the Effects of ASP5541 in Men with Advanced Prostate Cancer — Astellas Pharma Global Development, Inc.
- Phase III Study Comparing BNT324 and Docetaxel for Advanced Prostate Cancer — BioNTech SE
- Study on Copanlisib and Rucaparib for Metastatic Castration-resistant Prostate Cancer — Brown University
- Study on FG-3246 for Treating Advanced Prostate Cancer Resistant to Hormone Therapy — FibroGen
- Study on SYNC-T Therapy SV-102 for Men with Advanced Prostate Cancer — Syncromune, Inc.
- Study Comparing Xaluritamig Plus Abiraterone to Other Treatments in Patients with Advanced Prostate Cancer — Amgen
- Study Comparing BMS-986365 with Other Treatments for Advanced Prostate Cancer — Celgene
- Study on How PF-06821497 (Mevrometostat) Works in Men with Advanced Prostate Cancer — Pfizer
- Study on Inavolisib Treatment for Metastatic Castration-Resistant Prostate Cancer — Hoffmann-La Roche
- Study Comparing AZD2265 with Standard Treatments for PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) — AstraZeneca
- Phase 2a Study of High-Dose Testosterone Followed by Targeted Radioligand Therapy for Advanced Prostate Cancer — H. Lee Moffitt Cancer Center and Research Institute
- Phase 3 Study Comparing Xaluritamig with Cabazitaxel or Other Hormone Therapy in Patients with Advanced Prostate Cancer — Amgen
- Access to Niraparib and Abiraterone Acetate Combination for Advanced Prostate Cancer — Janssen Research & Development, LLC
- Study on PSMA [Lu-177]-PNT2002 Therapy for Treating Advanced Prostate Cancer After Hormonal Treatment — POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
- Study on Dato-Dxd Alone and with Other Cancer Treatments for Advanced Solid Tumors (TROPION-PanTumor03) — AstraZeneca
- Study on GVV858 Alone or with Hormone Therapy for HR+/HER2- Breast Cancer and Other Advanced Tumors — Novartis Pharmaceuticals
- Study on Olaparib Plus Abiraterone as First-line Treatment for Men with Advanced Prostate Cancer — AstraZeneca
- The COSMYC Trial: Testing a New Treatment Approach for Advanced Prostate Cancer — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study of 177Lu-TLX591 with Standard Care vs. Standard Care Alone in Patients with Advanced Prostate Cancer — Telix Pharmaceuticals (Innovations) Pty Limited
- Study on Treating Advanced Prostate Cancer with 177Lu-PSMA-617 — Ebrahim S Delpassand
- Study on XL092 for Patients with Advanced Prostate Cancer — University of Utah
- Study on [Lu-177]Ludotadipep for Treating Castration-resistant Prostate Cancer — FutureChem
- Study on 177Lu-PSMA-617 for Treating Advanced Prostate Cancer with Bone Marrow Involvement — M.D. Anderson Cancer Center
- Study on ONCT-534 for Treating Advanced Prostate Cancer — Oncternal Therapeutics, Inc
- Study on Checkpoint Inhibitors for Men with Advanced Prostate Cancer with Specific Genetic Changes — VA Office of Research and Development
- Study on the Safety and Effectiveness of REGN4336 Alone and with Other Drugs for Advanced Prostate Cancer — Regeneron Pharmaceuticals
- Study on Abemaciclib Before 177Lu-PSMA-617 for Treating Metastatic Castration-Resistant Prostate Cancer — Vadim S Koshkin
- Study on Abemaciclib With or Without Atezolizumab for Advanced Prostate Cancer — Dana-Farber Cancer Institute
- Study on the Anti-Tumor Effects of (177Lu) rhPSMA-10.1 Injection for Advanced Prostate Cancer — Blue Earth Therapeutics Ltd
- Study on Bortezomib for Treating Advanced Prostate Cancer with PTEN Deletion — University of Utah
- Study Comparing Cabazitaxel with or without Carboplatin to 177Lu-PSMA-617 in Advanced Prostate Cancer — Case Comprehensive Cancer Center
- Study on Ceralasertib Alone and Combined with Olaparib or Durvalumab for Patients with Solid Tumors — Rahul Aggarwal
- Study on Enfortumab Vedotin as a Single Treatment for Metastatic Castration-Resistant Prostate Cancer — University of Utah
- Study on FOR46 and Enzalutamide for Treating Advanced Prostate Cancer — Rahul Aggarwal
- Study on FPI-2265 for Patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer — Fusion Pharmaceuticals Inc.
- Study on ONC-392 and Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Advanced Prostate Cancer — OncoC4, Inc.
- Study on Pembrolizumab and 177Lu-PSMA-617 for Treating Advanced Prostate Cancer — University of California, San Francisco
- Pre-approval Access to Talazoparib for Patients with Advanced Prostate Cancer — Pfizer
- Expanded Access to MDV3100 for Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy — Astellas Pharma Global Development, Inc.
- Safety and Effectiveness of Oral Testosterone Followed by Enzalutamide for Men with Advanced Prostate Cancer — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study on Sipuleucel-T and Bipolar Androgen Therapy for Men with Advanced Prostate Cancer — Yale University
- Study on Zenocutuzumab for Patients with Specific Types of Cancer — Merus N.V.
- Study of INKmune in Patients With mCRPC (CaRe Prostate) — Inmune Bio, Inc.
- Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer — University of Utah
- Study on Pembrolizumab Combination Therapies for Advanced Prostate Cancer — Merck Sharp & Dohme LLC
- Study on SX-682 and Enzalutamide for Men with Advanced Prostate Cancer Resistant to Abiraterone — Syntrix Biosystems, Inc.
- Study on the Safety and Effectiveness of AsiDNA and Olaparib for Recurrent Solid Tumors — Valerio Therapeutics
- Study to Evaluate CCS1477 in Advanced Tumors — CellCentric Ltd.
- Study on Using High-Dose Testosterone with Darolutamide for Metastatic Prostate Cancer — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study on Targeted Alpha Therapy with 225Actinium-PSMA-I&T for Advanced Prostate Cancer — Fusion Pharmaceuticals Inc.
- Study on LAVA-1207 for Patients with Advanced Prostate Cancer Resistant to Treatment — Lava Therapeutics
- Study on XmAb®20717 (Vudalimab) Alone or with Chemotherapy or Targeted Therapy for Metastatic Castration-Resistant Prostate Cancer — Xencor, Inc.
- Study on ZEN003694 and Enzalutamide Compared to Enzalutamide Alone in Treating Advanced Prostate Cancer — Zenith Epigenetics
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Metastatic Castration-resistant Prostate Cancer to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.